Skip to main content
Boryung Corporation logo

Boryung Corporation — Investor Relations & Filings

Ticker · 003850 ISIN · KR7003850005 KO Manufacturing
Open in API
Filings indexed 354 across all filing types
Latest filing 2022-03-25 Share Issue/Capital Cha…
Country KR South Korea
Listing KO 003850

About Boryung Corporation

https://pharm.boryung.co.kr/eng/index.do

Boryung Corporation is a fully integrated healthcare company founded in 1957. Its core business encompasses the research, development, manufacturing, and global commercialization of pharmaceutical products, with a significant presence in the cardiovascular therapeutic area. The company is distinguished by its pioneering 'Care in Space' (CIS) initiative, which focuses on developing healthcare solutions for humans in extreme environments and leveraging space for new research opportunities. In addition to its pharmaceutical operations, Boryung functions as a healthcare investment company, fostering innovation across the health sector. The company's diverse portfolio includes prescription drugs, over-the-counter products, and a pipeline aimed at addressing future medical needs.

Recent filings

Filing Released Lang Actions
주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on the Granting of Stock Options) submitted to the Financial Services Commission/Korea Exchange. It details the issuance of stock options to executives, including the number of shares, exercise price, and vesting conditions. This type of disclosure regarding capital structure changes and equity-based compensation for directors/employees falls under the category of 'Share Issue/Capital Change' (SHA) in the provided classification schema.
2022-03-25 Korean
영업실적등에대한전망(공정공시)
Earnings Release Classification · 95% confidence The document is a 'Fair Disclosure' (공정공시) filing from Boryung Pharmaceutical, which provides forward-looking guidance on sales and operating profit for the 2022 fiscal year. It includes a comparison of previous forecasts versus actual results. Since this is a specific regulatory disclosure regarding financial outlook and performance projections, it falls under the category of general regulatory filings (RNS) as it does not constitute a full earnings release (which usually covers historical results) or a formal management report. FY 2022
2022-03-22 Korean
[기재정정]영업실적등에대한전망(공정공시)
Earnings Release Classification · 100% confidence The document is a regulatory filing from Boryung Pharmaceutical regarding a 'Forecast of Business Performance' (영업실적 등에 대한 전망). It includes a correction notice (정정신고) for a date error and provides forward-looking financial guidance (revenue and operating profit projections) for the 2022 fiscal year, along with a comparison of previous forecasts versus actual results. Since this is a formal regulatory disclosure of financial outlook and performance metrics, it falls under the category of general regulatory filings. FY 2022
2022-03-22 Korean
감사보고서제출
Audit Report / Information Classification · 100% confidence The document is titled '감사보고서 제출' (Submission of Audit Report) and provides a summary of the audit opinion and key financial data (assets, liabilities, revenue, profit) for the fiscal year. It explicitly states the auditor's name (Samil PricewaterhouseCoopers) and the date of receipt. While it contains financial data, it is a regulatory announcement regarding the filing of the audit report rather than the full annual report itself, fitting the criteria for a Report Publication Announcement (RPA). FY 2021
2022-03-17 Korean
사업보고서 (2021.12)
Audit Report / Information Classification · 100% confidence The document is a formal 'Audit Report' (감사보고서) for Boryung Pharmaceutical Co., Ltd. It includes the independent auditor's report, financial statements (Statement of Financial Position, Comprehensive Income Statement, Statement of Changes in Equity, Statement of Cash Flows), and detailed notes. It is not an Annual Report (10-K) as it focuses specifically on the audit and financial statements rather than the broader company activity, management discussion, and business outlook typical of a full 10-K. It is a standalone audit report. FY 2021
2022-03-17 Korean
주주총회소집공고
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a 'Notice of General Meeting of Shareholders' (주주총회소집공고) for Boryung Pharmaceutical. It contains the agenda for the upcoming Annual General Meeting (AGM), including items such as the approval of financial statements, election of directors, and dividend proposals. It also includes management information and financial data as reference materials for shareholders to vote on. This type of document is classified as a Proxy Solicitation & Information Statement (PSI) because it provides shareholders with the necessary information to exercise their voting rights at the meeting.
2022-03-10 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.